探索精神分裂症阳性与阴性症状量表五因素模型的共识。
Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia.
机构信息
Clinical Brain Disorders Branch, National Institute of Mental Health, NIH, Bethesda, MD 20892-1377, USA.
出版信息
Schizophr Res. 2012 May;137(1-3):246-50. doi: 10.1016/j.schres.2012.01.031. Epub 2012 Feb 21.
Abstract
Although the developers of the Positive and Negative Syndrome Scale (PANSS) grouped items into three subscales, factor analyses indicate that a five-factor model better characterizes PANSS data. However, lack of consensus on which model to use limits the comparability of PANSS variables across studies. We counted "votes" from published factor analyses to derive consensus models. One of these combined superior fit in our Caucasian sample (n=458, CFI=.970), and in distinct Japanese sample (n=164, CFI=.964), relative to the original three-subscale model, with a sorting of items into factors that was highly consistent across the studies reviewed.
摘要
虽然阳性和阴性症状量表（PANSS）的开发者将项目分为三个分量表，但因素分析表明，五因素模型能更好地描述 PANSS 数据。然而，对于使用哪种模型缺乏共识，限制了 PANSS 变量在研究之间的可比性。我们对已发表的因素分析进行了“计数”，以得出共识模型。其中一个模型在我们的白种人样本（n=458，CFI=.970）和独特的日本样本（n=164，CFI=.964）中表现出更好的拟合，与原始的三分量表模型相比，与综述研究中高度一致的项目分类因素相比。
相似文献
1
Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia.探索精神分裂症阳性与阴性症状量表五因素模型的共识。
Schizophr Res. 2012 May;137(1-3):246-50. doi: 10.1016/j.schres.2012.01.031. Epub 2012 Feb 21.
2
Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia.精神分裂症认知与正性和负性症状量表五因素模型。
Schizophr Res. 2013 Jan;143(1):77-83. doi: 10.1016/j.schres.2012.10.020. Epub 2012 Nov 30.
3
How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS.精神分裂症的阴性症状和认知障碍有多具特异性？对阳性和阴性症状量表及精神分裂症认知功能评定量表的分析
Cogn Neuropsychiatry. 2013 May;18(3):243-51. doi: 10.1080/13546805.2012.730995. Epub 2012 Nov 12.
4
Validation of a five-factor model of a Chinese Mandarin version of the Positive and Negative Syndrome Scale (CMV-PANSS) in a sample of 813 schizophrenia patients.在813例精神分裂症患者样本中对中文版阳性和阴性症状量表（CMV-PANSS）的五因素模型进行验证。
Schizophr Res. 2015 Dec;169(1-3):489-490. doi: 10.1016/j.schres.2015.09.011. Epub 2015 Oct 9.
5
The Brazilian standardization of the MATRICS consensus cognitive battery (MCCB): Psychometric study.MATRICS共识认知成套测验（MCCB）的巴西标准化：心理测量学研究。
Schizophr Res. 2017 Jul;185:148-153. doi: 10.1016/j.schres.2017.01.006. Epub 2017 Jan 17.
6
Scales for assessment of depression in schizophrenia: Factor analysis of calgary depression rating scale and hamilton depression rating scale.评估精神分裂症中抑郁的量表：卡尔加里抑郁评定量表和汉密尔顿抑郁评定量表的因子分析。
Psychiatry Res. 2017 Jun;252:333-339. doi: 10.1016/j.psychres.2017.03.018. Epub 2017 Mar 9.
7
Internal consistency, temporal stability and neuropsychological correlates of three cognitive components of the Positive and Negative Syndrome Scale (PANSS).阳性和阴性症状量表（PANSS）三个认知成分的内部一致性、时间稳定性及神经心理学相关性
Schizophr Res. 1999 Jul 27;38(1):27-35. doi: 10.1016/s0920-9964(99)00004-3.
8
Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the positive and negative syndrome scale.精神分裂症的精神病理综合征：阳性和阴性症状量表维度结构的评估
Schizophr Bull. 2000;26(1):167-77. doi: 10.1093/oxfordjournals.schbul.a033437.
9
Psychometric validation of the consensus five-factor model of the Positive and Negative Syndrome Scale.阳性与阴性症状量表共识五因素模型的心理计量学验证。
Compr Psychiatry. 2015 Oct;62:204-8. doi: 10.1016/j.comppsych.2015.07.015. Epub 2015 Jul 29.
10
Subscale structure for the Positive and Negative Syndrome Scale (PANSS): a proposed solution focused on clinical validity.阳性与阴性症状量表（PANSS）的亚量表结构：一个以临床效度为重点的解决方案。
Psychiatry Res. 2013 Jan 30;205(1-2):137-42. doi: 10.1016/j.psychres.2012.08.019. Epub 2012 Sep 10.
引用本文的文献
1
The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trial.GPR139激动剂TAK-041对精神分裂症患者脑血流和奖赏系统功能产生时间依赖性改变：一项随机安慰剂对照试验。
Psychopharmacology (Berl). 2025 Aug 16. doi: 10.1007/s00213-025-06884-x.
2
Recent cannabis use affects the association between baseline immune markers and long-term outcomes in psychosis.近期使用大麻会影响基线免疫标志物与精神病长期预后之间的关联。
Transl Psychiatry. 2025 Aug 14;15(1):282. doi: 10.1038/s41398-025-03498-x.
3
Binomial order is a speech marker of psychosis and thought disorder.二项式顺序是精神病和思维障碍的言语标记。
Sci Rep. 2025 Aug 6;15(1):28819. doi: 10.1038/s41598-025-14681-x.
4
Theory-of-mind improvement in schizophrenia after integrative cognitive remediation: which patients benefit more?综合认知康复治疗后精神分裂症患者心理理论能力的改善：哪些患者获益更多？
Schizophr Res Cogn. 2025 Jul 22;42:100380. doi: 10.1016/j.scog.2025.100380. eCollection 2025 Dec.
5
A dimensional approach to psychosis: identifying cognition, depression, and thought disorder factors in a clinical sample.一种针对精神病的维度方法：在临床样本中识别认知、抑郁和思维障碍因素。
Schizophrenia (Heidelb). 2025 Jul 14;11(1):97. doi: 10.1038/s41537-025-00641-x.
6
Altered cortical thickness associated with psychotic symptoms and cognitive profiles in involuntarily hospitalized, first-episode, drug-naive patients with schizophrenia.首次发作、未用药的精神分裂症患者非自愿住院时，皮质厚度改变与精神病性症状及认知特征相关。
Front Psychiatry. 2025 Jun 24;16:1596991. doi: 10.3389/fpsyt.2025.1596991. eCollection 2025.
7
White matter microstructure alterations in early psychosis and schizophrenia.早期精神病和精神分裂症中的白质微观结构改变
Transl Psychiatry. 2025 May 23;15(1):179. doi: 10.1038/s41398-025-03397-1.
8
Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial.阿立哌唑劳罗西酯每两个月一次或棕榈酸帕利哌酮每月一次用于治疗急性精神分裂症：ALPINE试验中PANSS五因素评分的事后分析
Neuropsychiatr Dis Treat. 2025 May 14;21:1047-1055. doi: 10.2147/NDT.S510471. eCollection 2025.
9
Role of peripheral cytokines and orbitofrontal cortex subregion structure in schizophrenia agitation.外周细胞因子和眶额皮质亚区结构在精神分裂症激越中的作用。
Sci Rep. 2025 Apr 23;15(1):14125. doi: 10.1038/s41598-025-99033-5.
10
COSMIN systematic review and meta-analysis of the measurement properties of the Positive and Negative Syndrome Scale (PANSS).COSMIN对阳性和阴性症状量表（PANSS）测量属性的系统评价与Meta分析。
EClinicalMedicine. 2025 Apr 11;82:103155. doi: 10.1016/j.eclinm.2025.103155. eCollection 2025 Apr.
本文引用的文献
1
Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling.基于潜在变量建模的精神分裂症患者功能水平相关因素。
Eur Psychiatry. 2012 Aug;27(6):396-400. doi: 10.1016/j.eurpsy.2011.01.010. Epub 2011 Jun 30.
2
Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.氨磺必利治疗精神分裂症的疗效：PANSS 五因子分析。
Schizophr Res. 2011 Sep;131(1-3):75-81. doi: 10.1016/j.schres.2011.05.018. Epub 2011 Jun 22.
3
The SIGMAR1 gene is associated with a risk of schizophrenia and activation of the prefrontal cortex.SIGMAR1 基因与精神分裂症风险和前额叶皮层激活有关。
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jul 1;35(5):1309-15. doi: 10.1016/j.pnpbp.2011.04.008. Epub 2011 Apr 28.
4
Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia.迈向下一代阴性症状评估：推进精神分裂症阴性症状评估的合作。
Schizophr Bull. 2011 Mar;37(2):291-9. doi: 10.1093/schbul/sbq104. Epub 2010 Sep 22.
5
Cognitive factor structure and invariance in people with schizophrenia, their unaffected siblings, and controls.精神分裂症患者、未受影响的兄弟姐妹和对照组的认知因素结构和不变性。
Schizophr Bull. 2011 Nov;37(6):1157-67. doi: 10.1093/schbul/sbq018. Epub 2010 Mar 29.
6
Principal-component analyses of PANSS and SANS-SAPS in schizophrenia: their stability in an acute phase.精神分裂症中 PANSS 和 SANS-SAPS 的主成分分析：急性期的稳定性。
Eur Psychiatry. 1995;10(2):97-106. doi: 10.1016/0924-9338(96)80320-8.
7
Theory of mind in schizophrenia: the role of clinical symptomatology and neurocognition in understanding other people's thoughts and intentions.精神分裂症中的心理理论：临床症状学和神经认知在理解他人思想与意图中的作用
Psychiatry Res. 2009 Jan 30;165(1-2):19-26. doi: 10.1016/j.psychres.2007.10.021. Epub 2008 Dec 14.
8
Insight, cognitive dysfunction and symptomatology in schizophrenia.精神分裂症中的洞察力、认知功能障碍及症状学
Eur Arch Psychiatry Clin Neurosci. 2008 Oct;258(7):402-5. doi: 10.1007/s00406-008-0809-8. Epub 2008 Apr 24.
9
Computerized measurement of negative symptoms in schizophrenia.精神分裂症阴性症状的计算机化测量
J Psychiatr Res. 2008 Aug;42(10):827-36. doi: 10.1016/j.jpsychires.2007.08.008. Epub 2007 Oct 24.
10
Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale.重新审视阳性与阴性症状量表的五个维度。
J Clin Psychopharmacol. 2007 Oct;27(5):431-6. doi: 10.1097/jcp/.0b013e31814cfabd.
Zotero 插件